Core Insights - Idorsia Ltd announces the presentation of long-term results from the lucerastat treatment at the 22nd Annual WORLDSymposium™, highlighting its potential as a first-in-class oral substrate reduction therapy for Fabry disease [1][7] Study Overview - The MODIFY study was a multicenter, double-blind, randomized, placebo-controlled trial involving 118 patients to assess the efficacy and safety of lucerastat as an oral monotherapy for Fabry disease [3] - The study did not meet its primary endpoint of reducing neuropathic pain but showed significant reductions in plasma and urinary Gb3 levels compared to placebo, sustained over time in the open-label extension [4][14] Long-term Efficacy - An interim analysis of the open-label extension revealed a notable reduction in the rate of eGFR decline among patients treated with lucerastat, suggesting a potential disease-modifying effect [5] - Patients with impaired renal function at baseline experienced a marked attenuation of kidney function loss, indicating lucerastat's promise in long-term organ protection [5][14] Kidney Biopsy Sub-study - A kidney biopsy sub-study evaluated Gb3 accumulation in key kidney cell types in male patients with classic Fabry disease who received lucerastat for at least two years, providing insights into its impact on renal disease biology [2] Patient Population and Disease Background - Fabry disease is a rare, X-linked lysosomal storage disorder caused by mutations in the GLA gene, leading to the accumulation of Gb3 and progressive damage across multiple organ systems [6][8] - Recent studies suggest a higher prevalence of Fabry disease than previously estimated, with over 21,000 diagnosed patients expected across the US, EU5, and Japan by 2034 [9] Current Treatment Landscape - Current treatment options for Fabry disease include enzyme replacement therapies and oral chaperone therapy, which have limitations, highlighting the unmet need for a well-tolerated, oral, disease-modifying therapy [10][11]

Core Viewpoint - Idorsia Ltd has entered into an exclusive license and supply agreement with EMS S.A. to commercialize QUVIVIQ™ (daridorexant) in Latin America, marking a significant step in the company's global expansion strategy [2][3]. Company Overview - Idorsia Ltd is focused on developing transformative medicines and aims to challenge existing medical paradigms [15][16]. - EMS S.A. is Brazil's largest privately-owned pharmaceutical company, with over 60 years of history and a strong market presence [13][14]. Product Information - QUVIVIQ is an innovative treatment for insomnia that selectively blocks orexin receptors, promoting restorative sleep without broadly suppressing brain activity [5][6]. - Clinical trials have shown that daridorexant significantly improves sleep onset, maintenance, and daytime functioning compared to placebo [6]. Market Potential - Insomnia affects millions in Latin America, with current treatments often leading to next-day drowsiness and dependence, indicating a clear unmet need for safer alternatives [4][11]. - The partnership with EMS is expected to enhance the availability of QUVIVIQ in Latin America, addressing the significant demand for effective insomnia treatments [3][7]. Financial Aspects - Idorsia is set to receive a total milestone compensation of USD 20 million for the execution of the agreement, along with supply prices and double-digit royalties on net sales in Brazil and Mexico [10].

Core Viewpoint - Idorsia Ltd is positioned for profitability and growth with two products entering the value-acceleration phase and a promising pipeline of innovative medicines [2][3] Highlights in 2025 - Idorsia achieved strong operational progress, including the global expansion of QUVIVIQ, which is on track to meet sales guidance of approximately CHF 130 million [7] - The company completed debt restructuring and secured new financing, extending its cash runway into 2028 [7] - Clinical validation for its synthetic glycan vaccine technology and initiation of a proof-of-concept trial with a CCR6 antagonist were also notable achievements [7] Areas of Focus in 2026 - The company aims to make QUVIVIQ the standard of care for insomnia and maximize the value of TRYVIO/JERAYGO for uncontrolled hypertension [3][7] - Plans include advancing lucerastat for Fabry Disease registration and progressing the Phase 2 proof-of-concept immunology portfolio [7] - Idorsia will continue to explore partnerships and new sales models for QUVIVIQ, as well as support potential descheduling in the US [7]

Core Insights - Idorsia Ltd has published results from the pivotal Phase 3 MODIFY study and its open-label extension, highlighting the potential of lucerastat as an oral substrate reduction therapy for Fabry disease, particularly in patients with renal impairment [1][3]. Study Overview - The MODIFY study was a multicenter, double-blind, randomized, placebo-controlled trial involving 118 patients, aimed at assessing the efficacy and safety of lucerastat as an oral monotherapy for adult patients with Fabry disease [2]. - The study's primary endpoint of reducing neuropathic pain over six months was not met; however, lucerastat showed significant reductions in plasma and urinary Gb3 levels compared to placebo, with sustained effects observed in the open-label extension [3][17]. Renal Function Insights - An interim analysis of the open-label extension indicated a notable improvement in renal function trajectory, with a reduced rate of eGFR decline in patients treated with lucerastat compared to their eGFR slope prior to enrollment [4][9]. - In patients with impaired renal function or fast-deteriorating eGFR at baseline, lucerastat was associated with a significant reduction in kidney function loss, suggesting a potential disease-modifying effect [4][17]. Long-term Treatment and Tolerability - The open-label extension has collected data from patients treated with lucerastat for over 42 months, with some receiving treatment for more than 6 years, demonstrating good tolerability and no serious treatment-related adverse events [5][8]. - A kidney biopsy sub-study was conducted to evaluate Gb3 inclusions in kidney cells of male participants with classic Fabry disease treated for over 3 years with lucerastat [5]. Future Directions - The company is collaborating with the US FDA to design a new Phase 3 program to ensure a regulatory pathway for lucerastat's approval [6][10]. - A post-trial access program is being established to ensure continuity of care for participants still receiving lucerastat at the study's closure [7].

Core Viewpoint - Idorsia Ltd has initiated a Phase 2 proof-of-concept trial for IDOR-1117-2520, an oral selective CCR6 receptor antagonist aimed at treating moderate-to-severe psoriasis, with potential implications for other autoimmune conditions associated with CCR6 and Th17 pathways [2][10]. Company Overview - Idorsia is focused on developing transformative medicines and aims to evolve into a leading biopharmaceutical company with a strong scientific foundation [13]. - The company is headquartered near Basel, Switzerland, and has a dedicated team covering all aspects of drug development [14]. Product Details - IDOR-1117-2520 is a first-in-class, oral small-molecule drug designed to block the CCL20-driven recruitment of pathogenic CCR6-expressing immune cells, showing efficacy comparable to existing IL-17 and IL-23 inhibitors in preclinical models [9]. - The drug is currently in a Phase 2 trial, with results expected in the first quarter of 2027 [6]. Clinical Trial Information - The Phase 2 trial is a multicenter, double-blind, randomized, placebo-controlled study involving approximately 30 participants, evaluating the efficacy and safety of two dosages of IDOR-1117-2520 over 12 weeks [6]. - Primary efficacy will be measured by the change in Psoriasis Area and Severity Index (PASI) score from baseline to Week 12 [6]. Mechanism of Action - The CCR6 antagonism targets a key receptor that directs pathogenic immune cells to inflamed tissues, potentially modulating inflammation without broad immunosuppression [8]. - The Th17 pathway, which is implicated in various autoimmune diseases, is a primary focus for IDOR-1117-2520, aligning with Idorsia's strategic goals [4][11].

Core Viewpoint - Idorsia Ltd has received the inaugural Prix Galien Bridges Award for its innovative treatment for insomnia disorder, highlighting the company's commitment to advancing patient care through scientific innovation [1][8]. Company Overview - Idorsia is focused on developing transformative medicines and aims to evolve into a leading biopharmaceutical company with a strong scientific foundation [13][14]. - The company is headquartered near Basel, Switzerland, and is listed on the SIX Swiss Exchange under the ticker symbol IDIA [14]. Product Details - The awarded treatment is a dual orexin receptor antagonist, recognized as the first and only drug of its kind approved in Europe for insomnia disorder [8][11]. - The development process involved synthesizing and characterizing over 25,000 compounds over a span of more than 10 years to achieve a drug that effectively improves both nighttime sleep and daytime functioning [3][11]. Recognition and Awards - The Prix Galien Awards, established in 1970, are considered the equivalent of the Nobel Prize for the life sciences industry, recognizing outstanding innovation and scientific advancement [3][5]. - The award received by Idorsia is particularly significant as it is the first of its kind in the Nordics, underscoring the company's innovative contributions to healthcare [2]. Insomnia Disorder Context - Insomnia disorder affects approximately 9.2% of the working-age population in Switzerland, characterized by difficulty in initiating or maintaining sleep, leading to significant daytime impairment [7][6]. - The orexin system plays a crucial role in regulating wakefulness, and its antagonism is key to restoring natural sleep architecture in patients with insomnia [10][11].

Core Insights - Idorsia Ltd has received the inaugural Prix Galien Bridges Award for its novel treatment for insomnia disorder, recognized as the "Best Biotechnology & Pharmaceutical Product" [1][7] - The award highlights the importance of scientific innovation in advancing patient care and acknowledges Idorsia's commitment to improving healthcare [2][3] Company Overview - Idorsia aims to challenge accepted medical paradigms by discovering, developing, and commercializing transformative medicines, positioning itself as a leading biopharmaceutical company [10][11] - The company is headquartered near Basel, Switzerland, and focuses on small-molecule drugs that can change treatment paradigms for various conditions [11] Product Development - The dual orexin receptor antagonist developed by Idorsia is the first and only drug of its kind approved in Europe for treating insomnia disorder, showcasing a significant breakthrough in life sciences [7][11] - The research team has been studying orexin and its receptors since 1998, leading to the development of a treatment that promotes natural sleep architecture while minimizing morning after-effects [3][8] Insomnia Disorder Insights - Insomnia disorder affects approximately 9.2% of the working-age population in Switzerland, characterized by difficulty in initiating or maintaining sleep, which significantly impacts daytime functioning [6] - The orexin system plays a crucial role in regulating wakefulness, and its overactivity is a key driver of insomnia, making it a target for therapeutic intervention [8]

Core Insights - New analysis confirms that aprocitentan significantly reduces blood pressure and albuminuria in patients with true resistant hypertension and high cardiovascular risk, including those with chronic kidney disease [1][3] Company Overview - Idorsia Ltd is set to present new findings from the Phase 3 PRECISION study of aprocitentan at the American Society of Nephrology Kidney Week 2025 in Houston, TX, from November 5 to 9, 2025 [2] - Aprocitentan is a once-daily, orally active dual endothelin receptor antagonist, approved as TRYVIO in the US for systemic hypertension treatment in combination with other antihypertensives since October 2024 [5] - The drug is also approved as JERAYGO for resistant hypertension treatment in the European Union, UK, and Switzerland, with a marketing authorization application under review in Canada [5] Clinical Findings - A poster presentation titled "Is Aprocitentan's Effect on Albuminuria Merely Due to Lowered BP? Subgroup Analysis of the PRECISION Trial" will take place on November 6, highlighting significant reductions in systolic blood pressure and Urine Albumin-to-Creatinine Ratio (UACR) compared to placebo across all subgroups [3] - The analysis indicates that the reductions in UACR are not solely due to lowered blood pressure, suggesting additional renal-protective mechanisms of aprocitentan, such as decreased glomerular permeability and functional tubular changes [3] Upcoming Events - Idorsia will also participate in the American Heart Association Scientific Sessions 2025 in New Orleans, LA, from November 7 to 10, with a symposium discussing the next era in hypertension treatment [4]

Core Insights - Idorsia Ltd has received marketing authorization from Swissmedic for JERAYGO (aprocitentan) to treat resistant hypertension in adults, marking it as the first and only endothelin receptor antagonist for this condition [1][8] - Resistant hypertension affects approximately 10% of hypertensive patients, highlighting the need for more effective treatment options [3] - JERAYGO has shown significant blood pressure reduction in diverse patient populations, including those with obesity, chronic kidney disease, or type 2 diabetes [4] Company Overview - Idorsia is focused on developing transformative medicines and has a strong scientific foundation, with JERAYGO representing their second product approval in Switzerland [4][15] - The company is in discussions with potential partners to expand the availability of JERAYGO across Switzerland and Europe [4] Product Details - JERAYGO is administered orally at a recommended starting dose of 12.5 mg once daily, which can be increased to 25 mg for patients needing tighter blood pressure control [1] - Aprocitentan, the active ingredient in JERAYGO, is a dual endothelin receptor antagonist that has been commercially available in the US as TRYVIO™ since October 2024 [12] Clinical Study Findings - The Phase 3 PRECISION study demonstrated that both 12.5 mg and 25 mg doses of aprocitentan significantly reduced sitting systolic blood pressure compared to placebo [10] - The treatment effect was consistent across various demographics, including age, sex, and race, and was evident within the first two weeks of treatment [10] Patient Demographics - The study included 730 patients with a mean age of 61.7 years, with a significant portion having comorbidities such as type 2 diabetes (54.1%) and chronic kidney disease (22.2%) [7][9] Safety Profile - Common adverse reactions to aprocitentan included edema/fluid retention and decreased hemoglobin levels, with specific contraindications for pregnant women and those with severe hepatic impairment [11]

Core Viewpoint - Idorsia Ltd, in collaboration with Stanford Hypertension Center and Duke Heart Center, has launched the IMPACT-HTN program aimed at modernizing the management of difficult-to-control hypertension through a multi-phase initiative that incorporates AI technology and real-world evidence [2][3][4]. Group 1: Program Overview - The IMPACT-HTN program consists of three phases designed to standardize treatment protocols and improve patient outcomes for those with difficult-to-control hypertension [2]. - The initiative will generate real-world evidence and develop scalable AI-powered tools to assist in identifying patients who may benefit from innovative therapies, including Idorsia's TRYVIO™ [2][5]. Group 2: Collaboration and Goals - The program is led by Dr. Vivek Bhalla from Stanford and Dr. Sreekanth Vemulapalli from Duke, emphasizing a cross-institutional collaboration to enhance care coordination and access to new therapies [3][4]. - The goal is to standardize evaluation and management practices for hypertension, ultimately improving patient outcomes and addressing the global health issue of hypertension, which affects approximately 50% of adults in the U.S. [3][4]. Group 3: Tools and Innovations - The program will introduce a digital care algorithm to standardize assessment and management of difficult-to-control hypertension, utilizing interactive tools such as AI chatbots and patient-facing algorithms [6]. - A personalized hypertension risk score will be developed to better identify patients at risk for negative cardiovascular outcomes, allowing for timely intervention [6]. Group 4: TRYVIO™ Overview - TRYVIO, a dual endothelin receptor antagonist, is now available for prescription and is indicated for patients whose hypertension is not adequately controlled with other medications [7][18]. - It has been included in the new clinical practice guidelines from the American College of Cardiology and the American Heart Association, highlighting its significance in the treatment landscape [7].